We Embrace Innovative Approaches to Clinical Development
Our clinical investigation programs focus on innovations that have the potential to deliver highly impactful therapies for serious liver diseases and potentially bring differentiated therapeutic benefits to patients.
ONGOING CLINICAL TRIALS
Recruiting
NCT06920043
This asset has been acquired by GSK. Further information can be found in the latest press release on gsk.com.
For more information, contact